- Conditions
- Glioblastoma
- Interventions
- Poly-ICLC, Tumor Treating Fields, Peptides
- Drug · Device · Biological
- Lead sponsor
- Adilia Hormigo
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2029
- U.S. locations
- 1
- States / cities
- The Bronx, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1201–1224
of 5,151
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lung Cancer, Melanoma, Skin Cancer
- Interventions
- Not listed
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Advanced Malignancies
- Interventions
- INCAGN01949, Nivolumab, Ipilimumab
- Drug
- Lead sponsor
- Incyte Biosciences International Sàrl
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 11 more
- Conditions
- High-grade Glioma, WHO Grade Ⅳ Glioma
- Interventions
- Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103
- Biological
- Lead sponsor
- Tcelltech Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Malignant Glioma, High Grade Glioma
- Interventions
- TTRNA-DC vaccines with GM-CSF, Dose-intensified TMZ, Autologous Hematopoietic Stem cells (HSCs), TTRNA-xALT, Td vaccine
- Biological · Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Gainesville, Florida
- Conditions
- Glioblastoma Multiforme, Gliosarcoma
- Interventions
- DSC-MRI
- Diagnostic Test
- Lead sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Providence, Rhode Island • Milwaukee, Wisconsin
- Conditions
- Glioblastoma Multiforme, GBM, Brain Cancer
- Interventions
- Autologous CMV-specific CTL
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Melanoma (Skin)
- Interventions
- hu14.18-IL2 fusion protein
- Biological
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Melanoma (Skin)
- Interventions
- CP-675,206
- Biological
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Meningioma, Anaplastic Oligodendroglioma, Brain Stem Glioma, Ependymoblastoma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Grade III Meningioma, Meningeal Hemangiopericytoma, Mixed Glioma, Pineal Gland Astrocytoma, Brain Tumor
- Interventions
- therapeutic allogeneic lymphocytes, aldesleukin, laboratory biomarker analysis, positron emission tomography
- Biological · Other · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Breast Cancer, Prostate Cancer, Melanoma (Skin), Endometrial Cancer, Gallbladder Cancer, Rectal Cancer, Kidney Cancer, Bladder Cancer
- Interventions
- Written Weight Loss Material, Weight Loss App, Behavioral Lifestyle Weight Loss Intervention (Coaching)
- Behavioral
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Recurrent Melanoma, Stage IV Melanoma
- Interventions
- cyclophosphamide, therapeutic autologous lymphocytes, aldesleukin, immunohistochemistry staining method, biopsy, laboratory biomarker analysis, immunologic technique, polymerase chain reaction
- Drug · Biological · Other + 2 more
- Lead sponsor
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Malignant Glioma
- Interventions
- REOLYSIN®
- Biological
- Lead sponsor
- Oncolytics Biotech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Los Angeles, California • Columbus, Ohio
- Conditions
- Genetic Predisposition, Paraganglioma, Pheochromocytoma, ALS, Parkinson Disease, Polyneuropathies, Frontotemporal Dementia, Alzheimer Disease, Cardiomyopathy Non-ischemic, Thoracic Aortic Aneurysm
- Interventions
- Behavioral nudge
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Refractory Neuroblastoma, Relapsed Neuroblastoma, High-risk Neuroblastoma, Retinoblastoma, Metastatic Retinoblastoma
- Interventions
- GPC2 CAR T cells
- Biological
- Lead sponsor
- Stephan Grupp MD PhD
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma, Skin Cancer
- Interventions
- LN-145, Cyclophosphamide, Fludarabine, Interleukin-2
- Biological · Drug
- Lead sponsor
- Karam Khaddour, MD, MS
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Malignant Melanoma
- Interventions
- Atezolizumab, Cobimetinib
- Biological · Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Detroit, Michigan + 3 more
- Conditions
- Glioblastoma, Recurrent Glioblastoma
- Interventions
- VB11, Surgery, Placebo, Bevacizumab
- Drug · Procedure · Other
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Boston, Massachusetts • San Antonio, Texas + 1 more
- Conditions
- Prostate Cancer, Breast Cancer, Cutaneous T-Cell Lymphoma, Lung Cancer, Melanoma
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 484 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Melanoma
- Interventions
- Tavo, Nivolumab, OncoSec Medical Electroporation Therapy System
- Drug · Device
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Melanoma Stage III, Melanoma
- Interventions
- nivolumab, Ipilimumab
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 3
- States / cities
- Durham, North Carolina • Lancaster, Pennsylvania • Philadelphia, Pennsylvania
- Conditions
- Recurrent Melanoma, Stage IIB Melanoma (Locally Advanced), Stage IIC Melanoma (Locally Advanced), Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma (Limited, Resectable)
- Interventions
- dabrafenib, trametinib, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Neuroendocrine Neoplasm, Gastroenteropancreatic Neuroendocrine Neoplasm
- Interventions
- Somatostatin Analogue(s)
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 2
- States / cities
- San Francisco, California • St Louis, Missouri
- Conditions
- Recurrent Malignant Glioma, Brain Glioblastoma
- Interventions
- OKN-007, Temozolomide (TMZ)
- Drug
- Lead sponsor
- Oblato, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Santa Monica, California + 10 more